| Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities EM Kerr, E Gaude, FK Turrell, C Frezza, CP Martins Nature 531 (7592), 110-113, 2016 | 310 | 2016 |
| Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis E Kerr, C Holohan, KM McLaughlin, J Majkut, S Dolan, K Redmond, ... Cell Death & Differentiation 19 (8), 1317-1327, 2012 | 109 | 2012 |
| The ERBB network facilitates KRAS-driven lung tumorigenesis B Kruspig, T Monteverde, S Neidler, A Hock, E Kerr, C Nixon, W Clark, ... Science translational medicine 10 (446), eaao2565, 2018 | 103 | 2018 |
| Differential affinity of FLIP and procaspase 8 for FADD’s DED binding surfaces regulates DISC assembly J Majkut, M Sgobba, C Holohan, N Crawford, AE Logan, E Kerr, ... Nature communications 5 (1), 3350, 2014 | 95 | 2014 |
| Metabolic rewiring in mutant Kras lung cancer EM Kerr, CP Martins The FEBS journal 285 (1), 28-41, 2018 | 80 | 2018 |
| Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity FK Turrell, EM Kerr, M Gao, H Thorpe, GJ Doherty, J Cridge, ... Genes & development 31 (13), 1339-1353, 2017 | 63 | 2017 |
| Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent JL Hurwitz, I Stasik, EM Kerr, C Holohan, KM Redmond, KM McLaughlin, ... European Journal of Cancer 48 (7), 1096-1107, 2012 | 51 | 2012 |
| Exploring the role of stromal osmoregulation in cancer and disease using executable modelling D Shorthouse, A Riedel, E Kerr, L Pedro, D Bihary, S Samarajiwa, ... Nature Communications 9 (1), 3011, 2018 | 21 | 2018 |
| The pseudo-caspase FLIP (L) regulates cell fate following p53 activation A Lees, AJ McIntyre, NT Crawford, F Falcone, C McCann, C Holohan, ... Proceedings of the National Academy of Sciences 117 (30), 17808-17819, 2020 | 20 | 2020 |
| General dentists’ attitudes and perceived barriers in providing domiciliary dental care to older adults in long‐term care facilities or their homes in Northern Ireland: A … E Kerr, S Watson, J McMullan, M Srinivasan, GJ McKenna Gerodontology 39 (3), 257-265, 2022 | 15 | 2022 |
| Clinical positioning of the IAP antagonist tolinapant (ASTX660) in colorectal cancer N Crawford, KJ Stott, T Sessler, C McCann, W McDaid, A Lees, C Latimer, ... Molecular cancer therapeutics 20 (9), 1627-1639, 2021 | 14 | 2021 |
| Metabolic reprogramming: A friend or foe to cancer therapy? C McCann, EM Kerr Cancers 13 (13), 3351, 2021 | 13 | 2021 |
| Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment H Egan, O Treacy, K Lynch, NA Leonard, G O’Malley, E Reidy, A O’Neill, ... Cell Reports 42 (5), 2023 | 12 | 2023 |
| KRAS allelic imbalance: strengths and weaknesses in numbers GJ Doherty, EM Kerr, CP Martins Trends in molecular medicine 23 (5), 377-378, 2017 | 6 | 2017 |
| Activation of innate-adaptive immune machinery by poly (I: C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer SM Corry, AMB McCorry, TRM Lannagan, NA Leonard, NC Fisher, ... Gut 71 (12), 2502-2517, 2022 | 5 | 2022 |
| Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features DJ Flanagan, R Amirkhah, DF Vincent, N Gunduz, P Gentaz, ... Nature Communications 13 (1), 7551, 2022 | 4 | 2022 |
| Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer SB Malla, RM Byrne, MW Lafarge, SM Corry, NC Fisher, PK Tsantoulis, ... Nature Genetics, 1-15, 2024 | 2 | 2024 |
| Rerouting the drug response: Overcoming metabolic adaptation in KRAS-mutant cancers DY Moss, C McCann, EM Kerr Science Signaling 15 (756), eabj3490, 2022 | 2 | 2022 |
| Stromal cell sialylation suppresses T cells in inflammatory tumour microenvironments: A new tumour stromal cell immune checkpoint? H Egan, O Treacy, K Lynch, NA Leonard, G O’Malley, K De Veirman, ... bioRxiv, 2021.06. 18.447879, 2021 | 2 | 2021 |
| Pathway level subtyping identifies a slow-cycling and transcriptionally lethargic biological phenotype associated with poor clinical outcomes in colon cancer independent of … SB Malla, RM Byrne, M Lafarge, SM Corry, NC Fisher, P Tsantoulis, ... | 1 | 2024 |
